Fisetin enhances cisplatin sensitivity in renal cell carcinoma via the CDK6/PI3K/Akt/mTOR signaling pathway

In conclusion, fisetin may enhance the sensitivity of RCC cells to cisplatin via the CDK6/PI3K/Akt/mTOR signaling pathway.PMID:38426151 | PMC:PMC10902757 | DOI:10.3892/ol.2024.14298

Source: Oncology Letters - March 1, 2024 Category: Cancer & Oncology Authors: Tingting Jiang Yan Liang Yenan Ji Yin Xue Source Type: research